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Summary
RARA becomes an acute promyelocytic leukemia (APL) oncogene by fusion with any of five translocation partners. Unlike
RARa, the fusion proteins homodimerize, whichmay be central to oncogenic activation. This model was tested by replacing
PML with dimerization domains from p50NFkB (p50-RARa) or the rapamycin-sensitive dimerizing peptide of FKBP12 (F3-
RARa). The X-RARa fusions recapitulated in vitro activities of PML-RARa. For F3-RARa, these properties were rapamycin
sensitive. Although in vivo the artificial fusions alone are poor initiators of leukemia, p50-RARa readily cooperates with an
activated mutant CDw131 to induce APL-like disease. These results demonstrate that the dimerization interface of RARa
fusion partners is a critical element in APL pathogenesis while pointing to other features of PML for enhancing penetrance
and progression.Introduction
Recurring chromosomal translocations are a hallmark of many
leukemias and are often associated with a specific leukemic
phenotype (Rabbitts, 1994). In the case of acute promyelocytic
leukemia (APL), all known disease-associated translocations in-
volve the retinoic acid receptor a (RARA) locus on chromosome
17, leading to the expression of leukemia-specific RARa fusion
proteins (Melnick and Licht, 1999). Although RARa normally re-
quires the heterodimer partner retinoid X receptor (RXR) to bind
DNA, the X-RARa fusion proteins overcome this dependence
and can efficiently bind target sequences as homodimers (de
The´ et al., 1990; Dyck et al., 1994; Goddard et al., 1991; Kaki-
zuka et al., 1991; Pandolfi et al., 1991).
Whereas five different N-terminal sequences in the fusion pro-
teins have been described, they all retain identical C-terminal
portions of RARa, supporting the proposal that the receptor
DNA binding domain (DBD) and ligand binding domain (LBD)
are important in the development of leukemia. In more thanCANCER CELL 9, 81–94, FEBRUARY 2006 ª2006 ELSEVIER INC. DOI 1099% of cases, RARa becomes fused to PML in a t(15;17) recip-
rocal translocation (Redner, 2002). PML is a RING finger protein
of the Trim/RBCC family. Special attention was initially given to
the fact that PML-RARa disrupts the normal localization of the
PML protein in PML oncogenic domains (PODs, also called
PML bodies), which are macromolecular proteinaceous com-
plexes in the nucleoplasm. This process is reversed by retinoic
acid treatment, which also triggers differentiation of the leuke-
mic cells (Dyck et al., 1994; Koken et al., 1994). The rarely de-
tected alternate fusion partners PLZF [t(11;17)], Nucleophosmin
[t(5;17) ], NuMA [t(11;17)], and STAT5b [(der17)], however, do not
affect PML domains. They do not share any obvious functional
or structural homologies, except for the presence of a dimeriza-
tion/oligomerization domain that is retained in the fusion protein.
In previous studies, we (Lin and Evans, 2000) and others
(Minucci et al., 2000) have shown that the PML-derived oligo-
merization domain of PML-RARa is essential for its biological
properties. Forced oligomerization of RARa can lead to similar
biological characteristics in vitro, such as enhanced binding ofS I G N I F I C A N C E
In acute promyelocytic leukemia (APL), retinoic acid receptor a (RARa), which functions as a heterodimer with the retinoid X receptor
(RXR), is converted to an oncoprotein by fusion to various partners (X-RARa) but most frequently to the PML protein. X-RARa fusions in-
teract with RXR but can also homodimerize, conferring expanded binding site specificity and suggesting that homodimerization may
be linked to oncogenic activation. We addressed this proposal by demonstrating that forced dimerization is sufficient for most in vitro
activities of X-RARa and can promote leukemogenesis in vivo. These results suggest that interferencewith spontaneous dimerization of
fusion proteins may provide a strategy for therapeutic intervention in acute myeloid leukemia..1016/j.ccr.2005.12.030 81
A R T I C L Ethe corepressors SMRT andN-CoR, and blocking differentiation
of myeloid cell lines.
The diversity of fusion partners and their implicated involve-
ment in apoptosis pathways (PML, PLZF, Nucleophosmin) has
created a controversy as to the exact extent of their contribu-
tion—in particular that of the PML protein—to leukemogenesis.
We have addressed this question by creating RARa fusions to
two heterologous oligomerization domains, which were then ex-
pressed in the hematopoietic compartment in mice. Since nei-
ther of the two artificial fusion proteins carries PML sequences
or affects the PML bodies, they represent suitable tools to dis-
sect the contribution of the RARa and PML pathways for leuke-
mogenesis, respectively.
The data obtained in this study demonstrate that artificial
X-RARa fusions recapitulate many of the activities of natural
PML-RARa oncoprotein in vitro, and that such activity is depen-
dent on dimerization. Although RARa dimers are poor inducers
of leukemia on their own when expressed in vivo, they can prime
mice for development of leukemia. Breeding of the p50-RARa
transgene into a Pml null background did not lead to increased
leukemia incidence, arguing that rather than simply having a
dominant-negative effect over RARa and PML pathways,
PML-RARa is a gain-of-function fusion.
Results
Design of X-RARa fusion proteins
One common feature of all RARa fusion proteins is the presence
of a homodimerization/homooligomerization domain. In order to
dissect this property from other biological activities, we fused
the common RARa part to two different heterologous dimeriza-
tion domains. In these X-RARa fusion proteins, the RARa part is
identical to that in the naturally occurring PML-RARa, PLZF-
RARa, NPM-RARa, NuMA-RARa, and STAT5b-RARa fusions.
In the first construct, we used the dimerization domain of the
NFkB p50 subunit (p50-RARa) (described previously in Lin and
Evans, 2000). In the second, we used the FK506 binding protein
(12 kDa) (FKBP12) (Amara et al., 1997). For FKBP12, we took
advantage of a constitutively dimerizing mutant (FKBP12F36M)
(Rollins et al., 2000). Dimerization of this mutant is abrogated
in the presence of its ligand rapamycin, and when fused in a re-
iterated manner, this protein creates a dimerization interface
that can be rapidly and reversibly regulated by rapamycin. We
created a head-to tail FKBP12F36M trimer fused to RARa (F3-
RARa). Figure 1A depicts a schematic overview of the proteins
used in this study.
Artificial X-RARa fusion proteins do not disrupt
PML nuclear bodies
We sought to separate abnormal dimerization of RARa from
other putative activities of proteins that are fused to RARa in
APL. Specifically, wewished to assesswhether the PML domain
of PML-RARa contributed to leukemogenesis through disrup-
tion of nuclear bodies, homodimerization, or both, or, possibly,
through a novel activity. In principle, the artificial X-RARa fusion
proteins should help to specifically delineate the importance of
homodimerization. We therefore examined whether these pro-
teins had an effect on endogenous PML distribution. To this
end, we used an MSCV-based retroviral vector to express
p50-RARa, F3-RARa, and as a control, PML-RARa in murine
ECoM-G cells (Sykes and Kamps, 2001). At 24 hr postinfection,82we performed a cytospin preparation of the cells followed by im-
munostaining. A monoclonal antibody (mAb) specific for murine
PML (Figure 1B,middle panels, FITC, green), togetherwith a rab-
bit antiserum specific for RARa, was used to detect transduced
X-RAR proteins (Figure 1B, top panels, Texas red) for double im-
munofluorescence staining. The anti-mouse PMLmAb does not
crossreact with human PML and is therefore unreactive with our
transduced PML-RARa. PML-RARa, p50-RARa, and F3-RARa
exhibit nuclear as well as some cytoplasmic staining. Nuclear
PML-RARa exhibits the expected microspeckled pattern (top
left panel), and F3-RARa and p50-RARa show a similar granular
nuclear localization (top, middle, and right panels, respectively;
expressing cells are marked by arrows). When stained for en-
dogenous mouse PML, PML-RARa-expressing cells (arrows)
exhibit a disrupted, almost invisible pattern, whereas neither
F3-RARa-expressing cells nor p50-RARa-expressing cells
had altered localization of PML. The bottom panels show the
Figure 1. X-RARa fusion proteins: Structure and effects on PML nuclear
bodies
A: Schematic representation of X-RARa fusion proteins used in the study.
RARa sequences were fused to the dimerization domain of the NFkB p50
subunit (p50 aa 250–353), or to three head-to-tail copies of the constitutively
dimerizing mutant F36M of the rapamycin binding protein FKBP12.
B: p50-RARa or F3-RARa proteins do not disrupt PML nuclear bodies. Murine
myeloid ECoM-G cells were infected with retroviral constructs expressing
PML-RARa, F3-RARa, or p50-RARa, respectively. Double immunofluores-
cence analysis was carried out with a monoclonal antibody (mAb) specific
for murine PML (middle panels, FITC) and a rabbit antiserum against RARa
(top panels, Texas red). PML-RARa, but not p50-RARa or F3-RARa, disrupts
the endogenous PML pattern. Human PML (and PML-RARa) is not recog-
nized by the mAb against murine PML (left, middle panel). The bottom
panels show the corresponding cells in the blue channel stained by Hoechst
33258 to visualize nuclei.CANCER CELL FEBRUARY 2006
A R T I C L EFigure 2. DNA binding and transcriptional properties of X-RARa fusion proteins
A: DNA binding of the X-RARa fusion proteins. Proteins were generated by in vitro translation. Increasing amounts of in vitro translated RXR, diluted in empty
reticulocyte lysate, were added in a total volume of 1 ml prior to the addition of labeled oligonucleotide. DNA binding of F3-RARa, but not of PML-RARa or
p50-RARa, is abrogated by addition of 2 mM rapamycin. A DR5 RARE was used for gel shift analysis. PML-RARabinds as a homodimer (arrow) and as an oligomer
(asterisk). RARa does not bind DNA in the absence of RXR (Ø, panel RARa). Addition of polyclonal antibodies against RXR (aRXR) or RAR (aRAR) to the binding
reaction results in a supershift of the corresponding complexes to the top of the lane, confirming that all analyzed fusion proteins are capable to form higher-
order complexes with RXR.
B: X-RARa fusion proteins mimic transcriptional properties of PML-RARa. HEK293 cells were transiently transfected with a DR1(3x)-Tk-Luciferase reporter con-
struct and expression constructs for the indicated proteins. The amount of each plasmid per well/48-well plate was as follows: PPARg/RXRa, 10 ng each;
PML-RARa, p50-RARa, or F3-RARa, each at 3, 10, or 30 ng. Repression of PPARg by PML-RARa was described previously. PPARg transactivation was induced
by addition of the ligand Ciglitizone (CGLZ). PML-RARa, p50-RARa, and F3-RARa repress ligand-dependent transactivation by PPARg in a dose-dependant
manner. Repression by F3-RARa is completely abrogated by addition of 2 mM rapamycin, arguing that RARa homomerization through the FKBP12 domain
is required for its repressive activity. The assay was performed in triplicate. Data are shown as mean 6 standard deviation.corresponding cells in the blue channel stained by Hoechst
33258 to visualize nuclei. Therefore, our immunostaining data
suggest that neither p50-RARa nor F3-RARa directly affects en-
dogenous PML.
Artificial X-RARa fusion proteins bind DNA as complexes
with RXR and repress transcription
Weassessedwhether our artificial fusion proteins are capable of
recapitulating crucial functional aspects of PML-RARa in vitro.CANCER CELL FEBRUARY 2006The ability of the fusion proteins to bind to retinoic acid response
elements (RAREs) was analyzed using electrophoretic mobility
shift assays (EMSA). Given the finding that higher-order PML-
RAR/RXR complexes contribute to the relaxed binding specific-
ity of PML-RAR, we examined DNA binding of RARa, p50-
RARa, F3-RARa, and PML-RARa to a DR5 element in vitro
with or without RXR (Figure 2A; each protein is shown in a sepa-
rate panel). Lane 1 for each protein shows binding in the ab-
sence of RXR, whereas lanes 2–4 in each panel show binding83
A R T I C L Ein the presence of increasing amounts of RXR. Lane 5 shows the
effect of rapamycin on binding when RXR is absent (compare to
lane 1). Lanes 6-8 demonstrate the ability of antibodies to RXR
(lane 6) or RAR (lane 8) to supershift the complexes as compared
to control serum (lane 7).
A number of observations were evident. First, the three fusion
proteins were capable of binding DNA in the absence of RXR.
Second, the addition of RXR altered the intensity and/or migra-
tion of the complexes for all three fusions. Third, in all cases
antibodies to RXR or RAR led to a specific supershift of the com-
plexes toward the top of the lanes. Fourth, disruption of dimer-
ization by addition of rapamycin eliminated binding of F3-RARa
to the response element when RXR was absent, whereas it did
not affect p50-RARa or PML-RARa binding. Fifth, the results for
PML-RARa differ somewhat from those for p50-RARa and F3-
RARa in that the majority of the complex migrates extremely
slowly (almost as slowly as the supershifted complex) after ad-
dition of the highest amount of RXR. These results confirm
that our artificial X-RARa fusion proteins bind to RAREs, demon-
strate that the binding of F3-RARa can be regulated by rapamy-
cin, and reveal similarities and differences in the complexes
formed by the artificial fusions as compared to PML-RARa.
PML-RARa is known to repress transcription induced by a
number of nuclear receptors, including RARs, VDR, and PPARs,
on an array of nuclear receptor response elements. The ability of
PML-RARa to influence transcription from more genes than
those impacted by RARa is due in part to a tolerance for various
spacing of nuclear receptor binding half-site motifs (Jansen
et al., 1995; Kamashev et al., 2004; Lin and Evans, 2000).
This relaxed binding site specificity may be a crucial aspect
for leukemogenesis by X-RARa fusion proteins. To address if
our X-RARa fusion proteins can similarly influence gene expres-
sion, we performed reporter gene assays using various nuclear
receptor responsive reporter constructs. As depicted in Fig-
ure 2B, like PML-RARa, the artificial fusion proteins efficiently
repress PPAR-dependent transcriptional transactivation from
a DR1-containing promoter in a luciferase-based reporter
gene assay (shown for PPAR-mediated transactivation). Similar
repression was observed for RXR/RXR (DR1)-, RXR/LXR (DR4)-,
and RXR/RAR (DR5)-dependent transactivation (data not
shown). When 2 mM rapamycin was added, repression by F3-
RARa was completely reversed (Figure 2B, last three columns),
whereas rapamycin had no effect on repression by PML-RARa
or p50-RARa (data not shown).
A myeloid cell line is immortalized by X-RARa
fusion proteins
Although it has been reported that PML-RARa can immortalize
normal myeloid progenitors (Altabef et al., 1996; Du et al.,
1999; Kamashev et al., 2004), this approach, with various varia-
tions, was unproductive in our hands. As an alternative, we
chose the ECoM-G cell line (Sykes and Kamps, 2001), which
was established from BALB/C lineage(2) murine bone marrow
cells, expressing an estrogen-responsive version of the pre-B
cell lymphoma fusion oncoprotein E2a-Pbx1. In the presence
of estrogen, ECoM-G cells are immortalized, whereas removal
of estrogen leads to retention of E2a-Pbx1 in the cytoplasm,
progressively followed by differentiation, growth arrest, and
cell death.
ECoM-G cells were infected with MSCV-based retroviral vec-
tors expressing PML-RARa, p50-RARa, or F3-RARa under con-84trol of the retroviral LTR. Infection was monitored by coexpres-
sion of the green fluorescent protein (GFP) from the samemRNA
via an internal ribosomal entry site (IRES). Twenty-four hours af-
ter infection, cells were washed and reseeded in mediumwith or
without estrogen. Strikingly, in the absence of estrogen, a GFP-
positive population of dividing cells took over within 3 weeks
(F3-RARa and p50-RARa) or 6 weeks (PML-RARa) (representa-
tive data shown in Figure 3A). No additional antibiotic selection
was performed, indicating that in the absence of estrogen (after
inactivation of the estrogen-responsive E2a-Pbx1) PML-RARa,
p50-RARa, and F3-RARa provide a selective advantage to the
expressing (GFP-positive) cells and permit immortalization.
Immature myeloid phenotype depends
on homodimerization
To address if forced dimerization is responsible for the ability of
X-RARa fusions to limit differentiation, we utilized the F3-RARa-
transformed ECoM-G cells. These cells were kept under normal
growth conditions or grown in the presence of 2 mM rapamycin.
In the presence of rapamycin (which leads to disruption of di-
merization), expression of the myeloid differentiation antigens
CD11b (Figure 3B) or Gr1 (data not shown) is upregulated in
ECoM-G/F3-RARa cells. In contrast, rapamycin has no differen-
tiative effect on ECoM-G cells that express PML-RARa. This re-
sult indicates that dedimerization reverses the ability of X-RARa
fusion proteins to impair differentiation.
p50-RARa and F3-RARa fusion proteins are poor
initiators of myeloid leukemia
As evident from our in vitro studies, artificial X-RARa fusion pro-
teins mimic many aspects of the PML-RARa protein, with the
notable exception that they do not interfere with PML and its
corresponding nuclear domains. To determine whether expres-
sion of X-RARa proteins can induce leukemia, transgenic mice
were generated that express p50-RARa or F3-RARa under con-
trol of the MRP8 promoter (previously used to generate PML-
RARA mice). Figure 4A shows Western blots demonstrating
expression of the corresponding transgenes in the bonemarrow
of transgenic mice. Of note, two of the three lines of F3-RARA
mice show only weak bands at the position of F3-RARa.
One hundred eighteen mice from three p50-RARA lines were
followed for 225–837 days. The characteristics of this cohort are
shown in Table 1. In transgenic line 1182, four animals devel-
oped myeloid leukemic pathology (at days 225, 394, 519, and
588), as assessed by cytology, histopathology, and flow immu-
nophenotyping (Figure 4B and data not shown). In two of the
mice for which peripheral blood was obtained, anemia and
thrombocytopenia were observed. One of the animals had leu-
kocytosis with significant numbers of maturing neutrophils. In
the other animal, the white blood cell (WBC) count was not ele-
vated, but circulating immature forms/blasts exhibited primary
granules in their cytoplasm (similar to MRP8 PML-RARA leuke-
mias), indicative of myeloid leukemia without maturation
(Figure 4B, mouse #2641). The pathological features in the other
three mice were most consistent with a diagnosis of myeloid
leukemia with maturation (Figure 4B, mouse #1750), although
myeloproliferative disease can not be excluded (Kogan et al.,
2002). We assessed the ability of one immature leukemia
(#2641) and one maturing leukemia (#2430) to engraft into sub-
lethally irradiated recipients. One million splenic cells from the
primary animals were injected into the lateral tail veins ofCANCER CELL FEBRUARY 2006
A R T I C L EFigure 3. Effect on ECoM-G cells of X-RARa fusion proteins
A: Expression of F3-RARa and p50-RARa, like that of PML-RARa, immortalizes myeloid-committed ECoM-G cells. ECoM-G cells were infected with GFP express-
ing retrovirus MIGR-IRES-GFP, or the corresponding virus expressing PML-RARa, p50-RARa, or F3-RARa. After infection, differentiation was induced by removal of
estrogen, and the cells were cultured for the indicated number of passages without further selective pressure. Plots were gated on live cells only (7AAD neg-
ative). Percentage of GFP-positive, 7AAD-negative cells (R2) is given in each dot plot. Cells were analyzed at passage numbers 1 and 7 postinfection for p50-
RARa and F3-RARa and at passage numbers 1 and 13 postinfection for PML-RARa. Cells infected with virus expressing only GFP usually undergo growth arrest
and die before passage 7. Cells infected with virus expressing p50-RARa, F3-RARa, or PML-RARa take over the population before P7 or P13, respectively.
B: F3-RARa-immortalized cells respond to rapamycin treatment. PML-RARa, p50-RARa, and F3-RARa cells were seeded in the respective growth medium in the
presence or absence of rapamycin and cultivated for 7 days. For the histogram analysis, live cells were gated as determined by negative 7AAD staining. Only
F3-RARa cells respond to rapamycin by increased expression of the differentiation marker CD11b.sublethally irradiated (4.5 Gy) recipient animals. Three of five
recipients of cells from #2641 or #2430 mice were observed to
develop leukemia (first illness at 66 days for recipients of leuke-
mia #2641, first illness at 126 days for recipients of leukemia
#2430).CANCER CELL FEBRUARY 2006We also followed 115 mice from two F3-RARA lines (Table 1)
as well as eight additional founder F3-RARA individuals for 113–
548 days. Similar to three of the diseased p50-RARA mice, two
F3-RARAmice (at days 229 and 717) developed disease consis-
tent with a diagnosis of myeloid leukemia with maturation85
A R T I C L EFigure 4. p50-RARA and F3-RARA transgenic
mice
A: Expression of X-RARa fusion proteins in bone
marrow of transgenic mice. Immunoblot of pro-
tein extracts. Extracts were derived from young
healthy animals or leukemic mice, as noted:
PML-RARa leukemia 935 of the 556 line; healthy
F3-RARa transgenic mice of lines 503, 496, and
107; FVB/n control; healthy p50-RARa transgenic
mice of lines 1186, 1182, and 1181; healthy PML-
RARa transgenic mouse of line 556; or as a con-
trol, extracts from in vitro translated proteins
(‘‘IVTL’’ lanes) using the Quick Coupled in vitro
translation system were used diluted 1:200 in
sample buffer, boiled, and loaded on the gel
(three lanes on the right). Positions of the PML-
RARa, F3-RARa, and p50-RARa proteins are
marked by arrows. (Bands at a molecular weight
similar to F3-RARa seen in lanes 1182 and 1181
represent a protein crossreacting with the poly-
clonal rabbit serum. Band at this position in the
PML-RARa 556 sample may represent crossre-
acting material and a degradation product of
PML-RARa.) Figure S1 is a second Western blot in-
cluded to show expression of p50-RARa in a leu-
kemic 1182 mouse, #2641.
B: Phenotype of leukemias in the p50-RARa and
F3-RARa mice. Shown are blood smears or
bone marrow cytospins (for mouse #496-37)
stained with Wright’s Giemsa, as well as hema-
toxylin and eosin-stained sections from sternum
(bone marrow), liver, and spleen, as indicated.
Mouse #1750 developed a differentiated-type
myeloid leukemia, characterized by mature
neutrophil-like cells in marrow and blood, similar
to mouse #496-37, whereas mouse #2641 pre-
sented with myeloid leukemia of blastic-type. In
all cases, infiltration of liver and spleen was ob-
served.(Figure 4B). Taken together, our artificial X-RARa constructs are
leukemogenic, but compared to a PML-RARA transgene they
give rise to leukemias at a reduced frequency and are less likely
to give rise to disease characterized by arrested maturation.
Fusion of PML to RARa is a gain-of-function mutation
It has been suggested that the oncogenic activity of PML-RARa
rests in its ability to act as a double dominant-negative protein,
inhibiting the normal activity of both RARa and PML. We have
shown that p50-RARa can inhibit RARa function but, lacking
PML sequences, should not interfere with endogenous murine
PML. In order to assess whether loss of PML function is what
distinguishes p50-RARa and PML-RARa, we crossed line p50-
RARA 1182, where we observed leukemias, into a Pml null86background. PML has been reported to have a central role in for-
mation of PML bodies (Ishov et al., 1999; Zhong et al., 2000a),
and loss of PML leads to an early onset of disease in a PML-
RARa transgenic/PML knockout model (Rego et al., 2001).
Hence, we hypothesized that lack of PML might mimic the dis-
ruption of PML bodies by the oncoprotein and restore leukemo-
genesis. The p50-RARA/Pml2/2 cohort of mice (Table 1, top,
last column) showed no evidence of increased incidence of leu-
kemia.We conclude from this that loss of PML does not comple-
ment p50-RARa in restoring leukemia-promoting activity to
a level comparable to PML-RARa. The lack of leukemias in these
p50-RARA/Pml2/2 mice suggests that the PML-RARa fusion
does not simply block PML and RARa function, but rather that
the fusion protein represents a gain-of-function mutation.CANCER CELL FEBRUARY 2006
A R T I C L ETable 1. Survival of X-RARA transgenic mice
Survival of PML-RARA transgenic micea
Transgenic line 556
Number of mice 36
Deaths 36
Leukemia 24
Not leukemia 12
Survival of p50-RARA transgenic mice
Transgenic line 1181 1182 1186 1182/Pml2/2
Number of mice 35 59 27 43
Deaths 27 50 17 8
Leukemia 0 4 0 0
Not leukemia 25 38 15 7
Unknownb 2 8 2 1
Follow-up: median, range (days) 554, 217–743 557, 225–761 497, 292–872 418, 290–659
Mice > 266 daysc 34 58 25 43
Survival of F3-RARA transgenic mice
Transgenic line 107 496 503
Number of mice 35 63 17
Deaths 9 9 2
Leukemia 1 1 0
Not leukemia 6 2 1
Unknownb 2 5 1
Follow-up
Follow-up: median, range (days) 531, 370–878 391, 361–618 390, 370–544
Mice > 266 daysc 35 63 17
aLeukemias developed in five of six lines of MRP8 PML-RARA transgenic mice (Brown et al., 1997). Line 556, which showed both the highest incidence of leu-
kemia and the greatest level of transgene expression as assessed by Western blotting, was studied further. In order to avoid the limiting effect of skin hyper-
plasia, bone marrow from young line 556 mice was transplanted into lethally irradiated recipient animals, and recipients were followed for the development of
leukemia. The results of these transplant studies are shown. The median time to leukemia in these transplanted animals was 266 days, with a range of 150–478
days.
bMice for which leukemia as a cause of death could be neither documented nor disproven.
cMedian time to leukemia in PML-RARA line 556 mice.We note that MRP8 PML-RARA mice, due to activity of this
promoter in skin, develop squamous papillomatous lesions
(Hansen et al., 2003). These lesions can be of such severity as
to interfere with breeding and to limit life span. We have not
observed this skin phenotype of p50-RARA or F3-RARA mice
in Pml+/+ mice. In support of a gain-of-function model, p50-
RARA/Pml2/2 mice do not exhibit abnormal skin.
p50-RARa, like PML-RARa, cooperates with an activated
cytokine receptor to generate leukemias with features
of APL
We and others have previously observed that activated cytokine
receptors cooperate with PML-RARa to rapidly induce myeloid
leukemias in mice (Kelly et al., 2002; Phan et al., 2003; Sohal
et al., 2003). We therefore wanted to address if p50-RARa,
although a poor inducer of leukemia on its own, might exhibit
cooperative leukemogenesis with cytokine receptor activation.
To assess this hypothesis, we transduced p50-RARA trans-
genic bone marrow with a retrovirus carrying an activated allele
of the bc chain of the GM-CSF/IL-3/IL-5 receptor (bcV449E,
CDw131) (Figure 5A). In these experiments, p50-RARa was ob-
served to readily cooperate with activated bc to cause leukemia.
The combination of activated bc with the p50-RARA 1182 trans-
gene caused leukemia with longer latency than bcV449E plus
the PML-RARA 556 transgene (median 85 days versus median
47 days, p < 0.0001). However, it is not clear that this difference
was due to differences in their protein structure (see below).
The leukemias that arose in recipients of p50-RARA bone
marrow transduced with bcV449E appeared similar to those inCANCER CELL FEBRUARY 2006PML-RARa/bcV449E recipients. The peripheral blood displayed
leukocytosis including immature forms/blasts, anemia, and
thrombocytopenia (Table 2). Bone marrows of p50-RARa/
bcV449E leukemias contained large immature forms/blasts
with prominent primary granules (Figure 5B). These leukemias
filled the red pulp of the spleen, engorged the liver (see Figure 5E,
below), andwere invasive in other tissues including lymph nodes
and kidneys. The leukemias arising in p50-RARa/activated bc
mice were readily transplantable and, like PML-RARa leuke-
mias, were responsive to retinoic acid. All-trans-retinoic acid
(ATRA) treatment of leukemias resulted in differentiation and re-
gression (Figures 5C–5H; Table 2) and enhanced survival time
(median survival of placebo-treated mice was 35 days versus
47 days for ATRA-treated animals; p = 0.04).
In our transduction experiments using transgenic bone mar-
row, expression of p50-RARa is directed to the myeloid lineage
by the hMRP8d promoter. Therefore, the development of mye-
loid leukemias might merely reflect restricted promoter activity.
PML-RARa, on the other hand, was reported to dictate myeloid
phenotype (Grignani et al., 2000;Minucci et al., 2002). In order to
further establish that p50-RARa could cooperate with an acti-
vated cytokine receptor to cause myeloid leukemia, we gener-
ated retroviral vectors that expressed p50-RARa or the bcr3/
short isoform of PML-RARa. Introduction of bone marrow that
had been doubly transduced with p50-RARa/bcV449E or
PML-RARa/bcV449E into mice led to leukemias within 9 weeks
postinfection/posttransplantation. Transduction leads to vari-
able levels of gene expression (dependent upon site of proviral
integration), and in contrast to the different latencies observed87
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leukemia
A: p50-RARa cooperates with a transduced retrovirus encoding an acti-
vated cytokine receptor to cause leukemia. Bone marrow of PML-RARA
transgenic (line 556) or p50-RARA transgenic (line 1182) mice were trans-
duced with retroviruses expressing bcV449E, and recipient mice were fol-
lowed for the development of leukemia. For comparison, results in recipients
of marrow from PML-RARA transgenic (line 556) animals transduced with
control retroviruses (pRUFneo-bcwt or MSCV-IRES-GFP) are shown. Nonleu-
kemic deaths were censored at the time of death. Graphs shown include
PML-RARa/bcV449E (n = 16), p50-RARa/bcV449E (n = 12), and PML-RARa/
control (n = 19). Results with bcV449E and control-transduced PML-RARA
bone marrow include some previously published animals (8 of 16 animals
for PML-RARa/bcV449E, 4 of 12 animals for PML-RARa/control; Phan et al.,
2003). The median latency of the 19 leukemias in recipients of PML-RARa
marrow transduced with control retroviruses was 304 days, which is not sig-88above when transgenic marrows were utilized, the latencies of
leukemias when normal bone marrows were doubly transduced
with p50-RARa/bcV449E or PML-RARa/bcV449E were not sig-
nificantly different (n = 9 for both groups; median 53 days versus
median 69 days; p = 0.20). This finding suggests that different
levels of expression of X-RARa fusions (e.g., as transgenes ver-
sus as retroviral vectors) influences their oncogenic potency.
The p50-RARa/bcV449E and PML-RARa/bcV449E double vi-
rus-induced leukemias exhibited overall similar cytology and
histopathology (data not shown), although a subtle decrease
in differentiation may be associated with the PML fusion relative
to the p50 fusion. Flow cytometric immunophenotyping re-
vealed diseases that exhibited essentially identical expression
of cell surfacemarkers (Table S1 in the Supplemental Data avail-
able with this article online). Our findingswith doubly transduced
bonemarrow cells confirm that an artificially dimeric X-RARa fu-
sion, like the PML-RARa fusion, can cooperate with an activated
cytokine receptor to generate myeloid leukemias. Interestingly,
Q-PCR analysis of p50-RARa/bcV449E leukemias as compared
to PML-RARa/bcV449E leukemias showed nearly identical pat-
terns of gene expression (Figure 6). Taken together, these data
support the idea that, in the context of additional mutations, di-
merization of RARa through its fusion partners both contributes
to transformation and underlies the promyelocytic phenotype
of APL.
Discussion
Since the discovery that, in addition to the classical PML-RARa
fusion, other RARa fusions can be found in APL patients (re-
viewed in Melnick and Licht, 1999), the significance of RARa fu-
sion partner pathways for promotion of APL development has
been a matter of intense debate. These partners, lacking further
obvious functional resemblance, all introduce a homooligomeri-
zation domain into the fusion protein. This raised questions
about the degree of fusion partner contribution in general—
and that of PML in particular—to leukemogenesis (Cheng
et al., 1999; Grignani et al., 1996; Pandolfi, 1996; Piazza et al.,
2001; Sachdev et al., 2001; Seeler and Dejean, 1999; Strudwick
and Borden, 2002; Wang et al., 1998; Zhong et al., 2000b). Spe-
cifically, the role of the disruption of PML bodies/PODs by PML-
RARa has been debated since PML protein localization was first
nificantly different from the latency of leukemias in untransduced PML-RARa
marrow (266 days). Hence, although the mutagenic effect of retroviral
transduction may be of relevance, under the conditions utilized for our stud-
ies it is expected that the activated nature of the bcV449E allele plays an im-
portant role in generating leukemias from marrow expressing the p50-RARA
transgene; it is unlikely that the high penetrance and short latency of the
p50-RARa/bcV449E leukemias results solely from insertional mutagenesis.
B: p50-RARa cooperates with an activated cytokine receptor to generate
immature forms/blasts with features of promyelocytes. A cytospin was pre-
pared with bone marrow cells of a leukemic p50-RARa/bcV449E mouse,
and cells were stained with Wright’s Giemsa stain.
C–H: p50-RARa/activated cytokine receptor leukemias respond to retinoic
acid. Mice were injected with p50-RARa/bcV449E leukemic cells. After 21
days, the mice were treated with placebo (C, E, and G) or ATRA (D, F,
and H). Four days later, the mice were euthanized. Representative images
are shown.Cand D: Bone marrow cytology, Wright’s Giemsa stain. Differen-
tiating neutrophils are evident in the ATRA-treated animal. E and F: Liver his-
topathology. ATRA markedly reduces leukemic infiltrate. Hematoxylin and
eosin. G and H: Splenic histopathology. ATRA restores nearly normal archi-
tecture in the spleen. Hematoxylin and eosin.CANCER CELL FEBRUARY 2006
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Leukemias in PML-RARa/bcV449E and
p50-RARa/bcV449E mice are
characterized by leukocytosis,
anemia, and thrombocytopenia
Normal PML-RARa/bcV449E p50-RARa/bcV449E
WBC (3103/ml) 3.9 6 2.5 86.0 6 45.0 51.6 6 8.9
HGB (mg/dl) 13.5 6 0.3 9.0 6 2.4 5.9 6 2.3
PLT (3103/ml) 1041 6 83 237 6 83 206 6 56
ATRA causes differentiation and regression
of p50-RARa/bcV449E leukemias
Immature forms/blastsa Intermediate formsa Mature neutrophilica Spleen weightb Liver weightb
Placebo 82.2 6 7.5 7.8 6 0.8 9.4 6 7.3 0.67 6 0.12 1.4 60.1
ATRA 20.2 6 4.7c 12.2 6 3.4 55.8 6 4.9c 0.20 6 0.06c 1.2 6 0.1c
Mean 6 SD.
Normal, n = 9; PML-RARa/bcV449E leukemias, n = 12; p50-RARa/bcV449E leukemias, n = 4; placebo and ATRA, n = 5.
Normal and PML-RARa/bcV449E leukemia data have been previously published (Phan et al., 2003).
aPercentage of total nucleated marrow cells.
bGrams.
cp < 0.05 compared to placebo.described (Dyck et al., 1994; Koken et al., 1994). We have ad-
dressed this question by replacing the PML domain of PML-
RARa with two biologically unrelated dimerization/oligomeriza-
tion domains.
Our study comes to the conclusion that interaction with the
cellular PML complex is not required for many PML-RARa activ-
ities, such as RXR-independent DNA binding, transcriptional
repression of a range of nuclear receptor response elements,
immortalization of ECoM-G cells, and inhibition of differentiation
of myeloid cell lines. Our data imply that the involvement of the
PML pathway in these in vitro activities is of lesser, if any, impor-
tance. In addition, by demonstrating that abrogation of F3-RARa
dimerization with rapamycin impairs the in vitro activities of the
fusion, our results underscore the important contribution of the
dimerization interface to the abnormal properties of the chimeric
proteins.
Interestingly, in vivo analyses of the leukemogenic potential of
p50-RARa and F3-RARa fusion proteins indicate that dimeriza-
tion of RARa is only one of the important properties of PML-CANCER CELL FEBRUARY 2006RARa. Although p50-RARa clearly was able to contribute to leu-
kemogenesis by sensitizing the cells to an activated cytokine re-
ceptor, it was a poor initiator of leukemia on its own. Likewise,
the second fusion protein, F3-RARa, resulted inmyeloid disease
at very low frequency and was able to sensitize cells to an acti-
vated cytokine receptor (data not shown). Both fusion proteins,
although biologically active in vitro, obviously lack an important
feature for leukemic induction, which is encoded in the PML do-
main. Further evidence for the importance of the PML domain to
the initiation of leukemia is provided by the lack of leukemias in
transgenic animals expressing a homodimerizing HDAC-RARa
fusion protein (Pier Paolo Pandolfi, personal communication).
These observations suggest that PML may be the most com-
mon partner of RARa because the PML-RARa fusion appears
to be the most potent initiator of leukemic transformation.
Several possibilities could explain the oncogenic potency of
the PML fusion. First, the PML domain may play a central role
in the initiation of leukemogenesis by virtue of disruption of the
PML nuclear bodies. Several studies have pointed out thatFigure 6. PML-RARa/bcV449E and p50-RARa/
bcV449E leukemias express similar levels of mye-
loid genes
RNA was prepared from PML-RARa/bcV449E
leukemic bone marrow (three leukemias from
PML-RARA transgenic marrow transduced with
bcV449E plus three leukemias from marrow
doubly transduced with PML-RARa + bcV449E)
or p50-RARa/bcV449E leukemic bone marrow
(three leukemias from p50-RARA transgenic mar-
row transduced with bcV449E plus two leukemias
from marrow doubly transduced with p50-RARa +
bcV449E). Results are presented in comparison
to normal bone marrow. Genes associated with
terminal neutrophil differentiation (Tgm2, Ltf,
Mmp9) are markedly decreased in the leuke-
mias compared to normal marrow. The expres-
sion of myeloblastin (Prtn3) is significantly lower
in PML-RARa/bcV449E leukemias than in p50-
RARa/bcV449E leukemias, suggesting that differ-
ent X-RARa fusions can have differential effects
on particular target genes (p < 0.05). Data are
shown as mean 6 standard deviation.89
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Quignon et al., 1998; Wang et al., 1998) and senescence (Fer-
beyre et al., 2000). A disruption of these postulated PML activi-
ties could very well establish a premalignant state that facilitates
the acquisition of or tolerance to additional genetic changes.
Second, recruitment of PML-associated factors to the PML-
RARa/RXR complex and its target genesmay have an important
impact on gene expression. Such PML-RARa-specific alter-
ations in the transcription of genes that regulate apoptosis, pro-
liferation, or differentiationmay underlie the ability of PML-RARa
to initiate leukemia. In consonance with this idea is recent work
indicating that mutation of K160 of PML, the major site of sumo-
lation, disrupts the ability of PML-RARa to enhance proliferative
potential in vitro and to initiate acute myeloid leukemias in vivo
(Zhu et al., 2005). Another possibility is that the PML domain
confers a specific conformational architecture to RARa DNA
binding complexes, for instance by the formation of higher-
order multimers as proposed previously (Minucci et al., 2000).
With regard to this possibility, our gel shift experiments show
that the RXR/p50-RARa and RXR/F3-RARa protein complexes
are not identical to those formed byRXR/PML-RARa (Figure 3A).
Hence, an important conformational effect of the PML domain
cannot be ruled out. Taken together, the data obtained in this
study indicate a very significant role of the PML domain in leuke-
mogenesis, perhaps through more than one molecular mecha-
nism.
PML-RARa was often suggested to be a double dominant-
negative mutant for both the RARa and the PML pathways (Pan-
dolfi, 2001). Lack of PML was reported to correspond to de-
creased levels of apoptosis in response to ionizing radiation
and Fas/TNF treatment (Wang et al., 1998). In addition, lack of
PML seems to prevent the localization of other PML-body asso-
ciated proteins to dot-like domains, instead leading to a diffuse
distribution (Ishov et al., 1999; Zhong et al., 2000a). To further
address the significance of the PML pathway in leukemogene-
sis, we bred the p50-RARA allele from the 1182 transgenic
line (the line in which we observed spontaneous leukemias)
into the Pml null background. We did not observe increased leu-
kemias in the p50-RARA/Pml null cohort. To avoid the complex-
ities associated with strain variability, we backcrossed the Pml
null allele more than ten generations into the FVB/N background
to obtain the line with which we performed these experiments.
These data argue against inactivation of PML being a sufficient
factor. Of note, because gene inactivation of Pml is not neces-
sarily equivalent to active disruption of PML nuclear bodies,
our data do not exclude the possibility that nuclear body disrup-
tion has a role in pathogenesis. In the absence of a robust func-
tional assay for PML (or the nuclear bodies of which they are
a part) to directly address this question, our data here provide
compelling evidence that the activity of PML-RARa is not merely
that of a double dominant-negative protein. Rather, our results
indicate that PML-RARa represents a true gain-of-function mu-
tation. The observation that low-level expression of PML-RARa
induces leukemia in mice is consistent with this gain-of-function
hypothesis (Westervelt et al., 2003).
Our findings support the hypothesis that dimerization of RARa
is critical to the leukemic phenotype of APL. Dimerized RARa is
tightly associated with the morphologic features of APL in hu-
mans and, in the right setting, with an APL-like disease in
mice. Dimerization of RARa through its fusion partners results
in alterations in binding site specificity (Hauksdottir and Prival-90sky, 2001; Jansen et al., 1995; Kamashev et al., 2004). This
change in binding site specificity also represents a gain-of-
function phenotype for X-RARa fusions because it extends the
repressive ability of these chimeras beyond the target genes
repressed by endogenous RARa. Future studies should eluci-
date how this expanded binding site specificity is important
for X-RARa oncogenesis.
Elegant experiments in mice have demonstrated that the level
of fusion protein expression (Westervelt et al., 2003) and prote-
olysis of PML-RARa by neutrophil elastase (Lane and Ley, 2003,
2005) make important contributions to the biological activities of
PML-RARa, including its ability to cause leukemic transforma-
tion. There may in fact be an important balance of activity
brought about by the combined impact of the level of protein
production and rate of proteolysis. In our experiments in
ECoM-G cells, we noted that initially, in contrast to findings
with the weakly leukemogenic artificial RARa fusions, few
PML-RARa-expressing cells were present 48 hr after transduc-
tion. This difference was due to induction of apoptosis by PML-
RARa in these cells (data not shown), and therefore more pas-
sages were required to observe domination of PML-RARa cells
in the cultures than for either of the artificial X-RARa fusions. This
observation is in line with previous studies indicating a toxic ef-
fect of PML-RARa onmany cell types that is dependent upon its
PML domain (Ferrucci et al., 1997). It is an intriguing possibility
that the level of expression of PML-RARa is of critical impor-
tance in human APL, and that the activities responsible for the
toxicity of the protein in certain settings might be the very
same activities that make PML-RARa more leukemogenic
than a random dimerizing X-RARa fusion. Ongoing (noted in
Lane and Ley, 2005) and future work may further delineate
such a connection.
Our data support the idea that PML-RARa-induced leukemo-
genesis is a multistep process, requiring cooperating events
that can also influence the phenotype. The rare spontaneous
leukemias that we observed in the p50-RARa transgenic cohort
were either of the blastic type (1 of 4) or of a more differentiated
type (3 of 4). This finding has some resemblance to the observa-
tions in the PLZF-RARa transgenic animals (Cheng et al., 1999;
He et al., 1998). In transgenic animals, the expression of PLZF-
RARa alone leads to development of a leukemia of amore differ-
entiated type, whereas coexpression of the reciprocal fusion
product RARa-PLZF produces a phenotype closely resembling
APL (He et al., 2000). In the context of a very strong cooperating
event such as activated bc, a dimeric RARa contributes to dis-
ease that is remarkably similar to that created with PML-RARa
under the same conditions, a disease with features of human
APL including responsiveness to ATRA therapy.
We propose that the PML-RARa oncoprotein has complex
activity that extends beyond disruption of PML and RARa func-
tions. These activities are in part described by our in vitro assays
but also involve an additional activity (or activities) of the PML
part of the fusion. Our results highlight the fact that a single ge-
netic event may contribute to transformation through multiple
mechanisms. We speculate that karyotypically simple AMLs
contain a few genetic lesions, each of which hasmultiple proleu-
kemic effects, whereas the karyotypically complex AMLs may
contain a large number of genetic lesions, each of which has
a simpler contribution to transformation.
It is evident that forced dimerization by fusion partners repre-
sents a tempting target for pharmacological intervention. OurCANCER CELL FEBRUARY 2006
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tion by rapamycin is sufficient to inactivate RXR-independent
DNA binding, repression, and block of myeloid differentiation.
A screen for chemicals that selectively bind the dimerization do-
main of PML and therefore selectively inhibit pathological RARa
dimerization could be a promising strategy for a targeted ther-
apy of PML-RARa-induced APL. More generally, pharmaco-
logic disruption of critical protein-protein interactions, including
abnormal dimerization, may enhance treatment response in
AML and other malignancies.
Experimental procedures
Recombinant plasmids
The p50-RARa construct has been described previously (Lin and Evans,
2000). Plasmid pSH-SF1E encoding the cDNA for FKBP12 followed by
a hemagglutinin tag was a gift from Dr. Steffan Ho, UCSD, Department of Pa-
thology. The F36M mutation was introduced using the QuikChange protocol
(Stratagene, La Jolla, CA). Trimerization was achieved using the 50-Xho1 and
30-Sal1 restriction sites. The resulting trimer was placed into the plasmid
pCMX-p50-RARa, replacing the p50 part, which gave rise to plasmid
pCMX-F3RAR. The translated breakpoint including the HA tag corresponds
to the amino acid sequence (FKBP12=)VELLKLEVDYPYDVPDYALDEFIET
QSSS(=RARa). This plasmid was used as a template for transfer into pMIGR
and phMRP8d by PCR cloning. pCMX-p50-RARa was modified by insertion
of a double-stranded oligonucleotide at the 50 end to permit transfer as a
BglII-BamHI fragment into pMIGR and phMRP8d. Plasmids pMIGR-PML-
RARa(s) and pMIGR-PML-RARa(l) were generated by insertion of an
EcoR1 fragment encoding the short (bcr3) PML-RARa isoform or the long
(bcr1) PML-RARa isoform into the corresponding restriction site of pMIGR,
an MSCV-based retroviral vector. pMIGR expresses inserted genes from
the viral LTR and contains an open reading frame for the enhanced green
fluorescence protein (EGFP) downstream of the multiple cloning site and
an IRES derived from EMCV. Infected cells can therefore be monitored by
their GFP expression. The pRufNeo retroviral constructs expressing bcwt
or bcV449E (CDw131) have been described before (Jenkins et al., 1995,
1999). Plasmids encoding PML-RARa, PPAR, LXR, RAR, RXR, and
pPPRE(Aox3x)tk-Luc used in the reporter gene assay have been described
previously (Lin and Evans, 2000; Lin et al., 1998; Nagy et al., 1997 and refer-
ences cited therein). Detailed sequence information is available upon re-
quest.
Cell culture, retroviral transduction, and immortalization
of ECoM-G cells
The estrogen-responsive ECoM-G cell line was kindly provided by David
Sykes and Mark Kamps (Sykes and Kamps, 2001). ECoM-G cells were cul-
tivated in IMDM (Gibco BRL) supplementedwith 10% fetal bovine serum, 1%
GM-CSF conditioned medium, and estrogen (1 mM). Retroviral packaging
was performed by transient transfection of 293 or BOSC23 cells (Pear
et al., 1993) using the pEcopac ecotropic packaging construct (Finer et al.,
1994) and the calcium phosphate method. Retroviral infection was per-
formed by spinoculation for 99 min at 2500 g in a total volume of 1–2 ml in
the presence of 0.1% v/v Lipofectamine. After spinoculation, viral superna-
tant was aspirated, and the cells were resuspended in IMDM/GM-CSF/
FBS without estrogen and split as needed. No antibiotic selection was per-
formed, so that changes in percentage directly reflect growth advantage or
disadvantage conferred by expression of the respective X-RARa protein. Ex-
pansion of infected cells was monitored by FACScan analysis of GFP+ cells
at every passage.
Gel shifts and reporter gene assays
Gel shifts and reporter gene assays were carried out essentially as described
before (Lin et al., 1998; Nagy et al., 1997). Proteins were produced by in vitro
translation using TNT Quick Coupled reticulocyte lysate (Promega, Madison,
WI). Bound complexes were run in 0.53 TBE PAA gels. For supershift exper-
iments, polyclonal antibodies against RARa and RXR were purchased from
Santa Cruz (Santa Cruz, CA) and diluted 1:20 (1 ml antibody per 20 ml binding
reaction). As a negative control, polyclonal antiserum against Pu.1 was used.CANCER CELL FEBRUARY 2006For reporter gene assays, usually 10 ng of receptor plasmid and 50 ng of re-
porter plasmid were transfected per well in 48-well plates into HEK293 cells,
using the TransIt LT1 transfection reagent (Mirus Corporation, Madison, WI).
Total DNA per well was filled up to 300 ng with salmon sperm DNA. Transfec-
tion efficiency was normalized by cotransfection of 5 ng pCMX-bGal per well.
All transfections were carried out in triplicate.
Mice
FVB/N mice were purchased from Jackson Laboratories or Harlan. Trans-
genic mice were generated by microinjection of linearized hMRP8d-p50-
RAR or hMRP8d-F3-RAR expression cassette into the pronuclei of fertilized
FVB/N oocytes, following standard procedures. All animal experiments and
care were carried out as approved by the corresponding UCSF and Salk In-
stitute Animal Protocol Review Committee and in accordance with AAALAC
guidelines. hMRP8d-PML-RARa mice have been previously described
(Brown et al., 1997). Mice were observed daily for signs of illness. When
any abnormality was observed, mice were subjected to a brief physical ex-
amination. Blood was obtained on animals that showed signs of illness and
also in selected animals to screen for unsuspected disease. Mice were sac-
rificed when moribund or when physical examination and blood cell counts
indicated likely rapid progression of illness.
Western blot analysis
Bone marrow was obtained by flushing buffered saline through mouse long
bones. Total cell lysates from equal numbers of unfractionated bone marrow
cells from control and transgenic mice were used. Western blot analysis was
performed as described (Robbins et al., 1995) with rabbit polyclonal antise-
rum raised against a glutathione S-transferase fusion protein encompassing
amino acids 420–462 of the human RARa protein (Gaub et al., 1992). In vitro
translated samples were diluted 1:200 in SDS sample buffer.
Transduction of primary bone marrow
Donor mice were treated with 150 mg of 5-fluorouracil/kg, and marrow was
harvested 5 days later. Marrowwas prestimulated for 24 hr in Myelocult 5300
or StemSpan (StemCell Technologies) with 100U of penicillin G/ml, 100 mg of
streptomycin/ml, 2mML-glutamine, 6 ng ofmIL-3/ml, 10 ng ofmIL-6/ml, and
10 ng of stem cell factor/ml in 12- or 24-well plates at 1–2 3 106 cells/well.
Fifteen percent heat-inactivated fetal bovine serum and 5% X63Ag8-mIL-3
conditioned medium was also present for most experiments. BOSC23 cells
were transfected with retroviral constructs. Marrow was transduced by spi-
noculation with either 2 ml of fresh retroviral supernatants (filtered through
0.45 mmfilters) or 1ml of each retroviral supernatant at 1100 g in the presence
of 2 mg of Polybrene/ml for 1.5 hr on 2 consecutive days. Infection efficiency
was assessed by FACScan analysis 24 hr after the second spinoculation. Un-
sorted cells after transduction were introduced into lethally irradiated mice
(total of 9 Gy, in two equal doses 3–6 hr apart).
Peripheral blood counts and bone marrow differential counts
Blood was obtained from the retro-orbital sinus and anticoagulated with
EDTA or heparin. WBC count, hemoglobin level, and platelet counts were
measured with the Hemavet 850 cell counter (CDC Technologies) or by An-
tech diagnostics. Blood smears and bone marrow smears or cytospins and
were stained withWright’s Giemsa stain or DiffQuick staining (Dade Behring).
Peripheral blood differential WBC counts and bone marrow differential
counts were determined by morphology as previously described (Kogan
et al., 2002).
Histopathology
Tissues were initially fixed in either 10% buffered formalin solution (Fisher
Scientific), 4% paraformaldehyde in PBS, or Bouin’s fixative. Sternums fixed
in formalin were decalcified for 3 hr prior to embedding (11% formic acid, 8%
formaldehyde). Paraffin-embedded sections were stained with hematoxylin
and eosin (H&E), following standard protocols.
Immunophenotyping
After depletion of red blood cells, 100,000 to 300,000 bone marrow and/or
spleen cells were resuspended in 100–200 ml of fluorescence-activated
cell-sorting buffer (buffered saline with 2% heat-inactivated fetal bovine se-
rum and 2.5% cell dissociation buffer [Gibco-BRL]). Cells were incubated
with unlabeled anti-CD16/CD32 antibodies (Fc block) for 15 min prior to91
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isothiocyanate (FITC)-conjugated antibodies to CD24, Ly-71(F4/80), CD71,
CD34, CD16/32, I-A, CD41, IgD, CD45R(B220), CD8a, CD90, IgK, and TCRa/b;
phycoerythrin (PE)-conjugated antibodies to Ly-71(F4/80), Ly-76(Ter119),
CD31, Ly6A/E (sca-1), CD117(c-kit), CD86, IgM, CD5, CD3, and CD138(syn-
decan-1); Tricolor-conjugated antibodies to Ly6G(Gr-1), CD11b(Mac-1),
CD45, CD4, CD19, and TCR g/d; biotin-conjugated antibodies to Ly6G
(Gr-1), CD59, and human bc. Antibodies were incubated with the cells for
20 min in the dark on ice. Stained cells were washed, and then only cells
stained with biotin-conjugated antibodies were stained with Streptavidin-
APC for another 20min in the dark. The cells were analyzed on a FACSCalibur
apparatus (Becton Dickinson), and at least 10,000 events were collected for
each sample. Fluorescence-activated cell sorting data were analyzed with
CellQuest (Becton Dickinson). Alternatively, approximately 300,000 cells
were resuspended in PBS/2% FBS and stained with a 1:100 dilution of the
corresponding phycoerythrin or FITC/Cy2-conjugated antibody (Pharmin-
gen). For viability staining, cells were incubated in a solution of 7 aminoacti-
nomycin D (7AAD) (20 mg/ml) in PBS/2% FBS. Analysis was performed using
a BD-FACScan flow cytometer (BD Biosciences) and the CellQuest or FloJo
software packages. FSC and SSC gates were set to exclude residual eryth-
rocytes and dead cells where necessary.
Quantitative polymerase chain reaction
Bonemarrow cells harvested from the long bones of normal or leukemicmice
were initially cryopreserved. Subsequently, the cells were thawed and centri-
fuged (600 g), and RNAwas immediately isolated by extraction with TriZol re-
agent (#TR118, Molecular Research Center Incorporated) according to the
manufacturer’s protocol (http://www.mrcgene.com/tri.htm). Reverse tran-
scription (RT) and quantitative polymerase chain reaction (Q-PCR) were per-
formed at the UCSF Comprehensive Cancer Center Genome Core Facility.
TaqMan Gene Expression Assays from Applied Biosystems for the following
genes were utilized: Cebpa,Gcsfr, Ltf, Lys,Mmp9 (Gelatinase B),Mpo,Myc,
Prtn3 (Myeloblastin), Sfpi1 (PU.1), and Tgm2. Percent of gene expression
was normalized to mouse Gapdh expression. Each gene was assessed in
triplicate for each sample.
Pathologic diagnosis
Gross pathology, blood cell counts, blood smears, bone marrow and splenic
cytology, histopathology, and flow cytometric immunophenotyping were
used for diagnosis of hematopoietic neoplasms according to published
guidelines (Kogan et al., 2002).
Briefly, myeloid leukemia was diagnosed by hepatosplenomegaly with in-
filtration of leukemic cells into peripheral tissues outside the spleen and
lymph nodes, as well as expansion of leukemic cells in the bone marrow
with reduction of normal hematopoietic elements (resulting in peripheral ane-
mia and thrombocytopenia).
Supplemental data
The Supplemental Data include one supplemental figure and one supple-
mental table and can be found with this article online at http://www.
cancercell.org/cgi/content/full/9/2/81/DC1/.
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